Last reviewed · How we verify
Full course of PD-1 monoclonal antibody
Full course of PD-1 monoclonal antibody is a PD-1 inhibitor Small molecule drug developed by Ming-Yuan Chen. It is currently in Phase 3 development for Advanced or metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.
A monoclonal antibody that binds to PD-1 on immune cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses.
A monoclonal antibody that binds to PD-1 on immune cells, blocking the interaction with PD-L1/PD-L2 on tumor cells and restoring anti-tumor immune responses. Used for Advanced or metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.
At a glance
| Generic name | Full course of PD-1 monoclonal antibody |
|---|---|
| Sponsor | Ming-Yuan Chen |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 is an immune checkpoint receptor that, when engaged by tumor-expressed ligands (PD-L1/PD-L2), suppresses T-cell activation and allows tumors to evade immunity. PD-1 monoclonal antibodies prevent this inhibitory signal, thereby reactivating exhausted T cells and enhancing their ability to recognize and kill cancer cells. This mechanism has proven effective across multiple solid and hematologic malignancies.
Approved indications
- Advanced or metastatic melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Hodgkin lymphoma
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
Key clinical trials
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma (PHASE3)
- A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Full course of PD-1 monoclonal antibody CI brief — competitive landscape report
- Full course of PD-1 monoclonal antibody updates RSS · CI watch RSS
- Ming-Yuan Chen portfolio CI
Frequently asked questions about Full course of PD-1 monoclonal antibody
What is Full course of PD-1 monoclonal antibody?
How does Full course of PD-1 monoclonal antibody work?
What is Full course of PD-1 monoclonal antibody used for?
Who makes Full course of PD-1 monoclonal antibody?
What drug class is Full course of PD-1 monoclonal antibody in?
What development phase is Full course of PD-1 monoclonal antibody in?
What are the side effects of Full course of PD-1 monoclonal antibody?
What does Full course of PD-1 monoclonal antibody target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Ming-Yuan Chen — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic melanoma
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Renal cell carcinoma
- Compare: Full course of PD-1 monoclonal antibody vs similar drugs
- Pricing: Full course of PD-1 monoclonal antibody cost, discount & access